{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/urticaria/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"3daa7b54-d234-587b-8a56-1bb5cae1efe4","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 9410f87c-7c6f-4911-b891-9d902cd4ae6d --><h2>Changes</h2><!-- end field 9410f87c-7c6f-4911-b891-9d902cd4ae6d -->","summary":null,"htmlStringContent":"<!-- begin item 2554b906-cdba-45c7-aae1-cadf12e66f89 --><!-- begin field f433c22f-7165-44ee-bdba-1760f1090f2f --><p><strong>March 2020</strong> — minor update. Topic updated in line with revised SPC on non-sedating antihistamines.</p><p><strong>January 2018</strong> — minor update. Adverse effect section of non-sedating antihistamines updated to reflect changes to SPC.</p><p><strong>March 2017</strong> — reviewed. A literature search was conducted in March 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key controlled trials (RCTs) published since the last revision of the topic. Changes to the topic include:</p><ul><li><strong>New classification of chronic urticaria:</strong> based on the <em>BSACI guideline for the management of chronic urticaria and angioedema </em>published by the British Society for Allergy and Clinical Immunology<em>, </em>chronic urticaria is now classified as (Powell, 2015):<ul><li>Chronic spontaneous urticaria (CSU, previously called chronic idiopathic urticaria).</li><li>Autoimmune urticaria (in European guidelines this comes under the CSU subtype).</li><li>Chronic inducible urticaria (previously called physical urticaria).</li></ul></li><li><strong>Length of treatment course:</strong> people with symptoms requiring treatment should be offered a suitable non-sedating antihistamine at the standard licensed dose to be taken daily for up to 4 weeks. Once symptom control has been achieved, antihistamine treatment should be taken daily for<strong> </strong>3–6 months (for most people) or as required or prophylactically (for people with infrequent symptoms). </li><li><strong>Updosing of non-sedating antihistamines: </strong>for people not responding to standard doses of antihistamines,<strong> </strong>the dose of the<strong> </strong>first choice antihistamine should be increased gradually to up to four times the standard licensed dose (if appropriate). </li><li><strong>Assessing disease severity and impact on quality of life: </strong>this update includes the recommendation to consider assessing disease severity and impact on quality of life using validated tools, such as the Urticaria Activity Score (UAS7) and the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL), respectively.</li></ul><!-- end field f433c22f-7165-44ee-bdba-1760f1090f2f --><!-- end item 2554b906-cdba-45c7-aae1-cadf12e66f89 -->","topic":{"id":"bfdbbcbf-5a56-51b8-b0aa-78a059b4cfec","topicId":"73ccd3ba-b5a5-4a3c-98b2-d838dd8a3c58","topicName":"Urticaria","slug":"urticaria","lastRevised":"Last revised in March 2020","chapters":[{"id":"7068e840-7bdb-5596-a56f-1c930bd4b8c4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"d6e4cfbd-5e36-5755-a780-8091e4b5f146","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9dde1c08-758f-55bb-b187-0203ded94048","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3daa7b54-d234-587b-8a56-1bb5cae1efe4","slug":"changes","fullItemName":"Changes"},{"id":"54c42276-0c06-5c18-825f-3c440cb30dfe","slug":"update","fullItemName":"Update"}]},{"id":"5cff12c3-445b-5613-bf5d-dc48effe6502","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"9abed54c-a9ed-58d4-bfce-3f0dddd49698","slug":"goals","fullItemName":"Goals"},{"id":"c2f713b4-e2ec-5e5e-be8f-5c4285be0b6e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"e829abf6-8412-500f-9425-647958addf97","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"92b040fe-6318-560a-9ae0-6f98a6aa9c09","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"2d2f38df-88c4-5895-915d-199eefc9b02a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d51180cd-461f-58ad-8f03-20d63965abfb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a7fce165-b445-5aa6-9ec9-6ec8016f4bee","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a5d17f35-ddfe-5931-bfe4-b7dc039baea0","slug":"definition","fullItemName":"Definition"},{"id":"90888c1e-cd37-5fdf-9d0d-b71e51bf56c3","slug":"causes-trigger-factors","fullItemName":"Causes/trigger factors"},{"id":"76d2cc5e-4a3e-5032-8eed-d4010ace1ae7","slug":"prevalence","fullItemName":"Prevalence"},{"id":"507a6931-af71-54ae-a8e7-2b4393c2a41b","slug":"complications","fullItemName":"Complications"},{"id":"091f4740-5801-5ac0-83bd-a7ebbc2a2848","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"fc3a9cf3-3dd4-5456-94e1-90c38c83a0b1","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"513fb45b-36c0-59b5-8f88-13b10509caee","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"e2100cac-0eb7-55e6-b138-9cbc110f1b71","slug":"investigations","fullItemName":"Investigations"},{"id":"2da7bf77-7798-5632-97d4-64d5463f8cde","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"1a1cabda-9d82-5131-8852-db2d844e0b46","fullItemName":"Management","slug":"management","subChapters":[{"id":"f797a7bd-9ca9-523b-8f1e-e2afc927c4ab","slug":"managing-urticaria","fullItemName":"Scenario: Managing urticaria"}]},{"id":"3c7854e6-2fe5-5632-9b63-69f2773b7dd1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"71f6ce5f-ac94-5ef4-9a02-0aa362883a44","slug":"non-sedating-antihistamines","fullItemName":"Non-sedating antihistamines"},{"id":"8888f0f6-7dd8-55fb-afc0-9e5df55b825a","slug":"sedating-antihistamines","fullItemName":"Sedating antihistamines"},{"id":"b8336773-e3de-5ec0-a85b-93fd72ff7869","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"}]},{"id":"c88fe5a9-a559-5661-9a1f-e0ee93078a4d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e9950b4f-8af1-5d4b-b531-431ac4a731bb","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"729aa2a2-070b-51ed-9ecf-c29549914b66","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a30a2a17-7629-5022-a313-848d8264fb35","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f6d1c75a-6a3d-5326-97ca-baff36370740","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"dd5a897e-e7d5-5c98-88b6-35014f9a5dde","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6d27a969-ded2-5d9d-9321-f65e47426edf","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0d45859d-1b50-538f-84fa-568f43b5c283","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9dde1c08-758f-55bb-b187-0203ded94048","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"2ff5ae32-6d3d-5fa8-a0bd-9f506fc16e13","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 806841f8-dd5b-4561-8525-fc306ba18a13 --><h3>Previous changes</h3><!-- end field 806841f8-dd5b-4561-8525-fc306ba18a13 -->","summary":null,"htmlStringContent":"<!-- begin item d8dea68b-59e2-4018-becd-f56788edb72c --><!-- begin field b6503804-2eaf-490d-93cc-1f57cfca5c53 --><p><strong>May 2016</strong> — minor update. Text updated to reflect the Medicines and Healthcare products Regulatory Agency (MHRA) safety update on the risk of QT interval prolongation and Torsade de Pointes with hydroxyzine (MHRA, 2015). </p><p><strong>May 2014</strong> — minor update. A link to antihistamine prescriptions has been removed and replaced with a link to a prescribing information section with information on licensed doses of antihistamines.</p><p><strong>November 2011</strong> — revised. A literature search was conducted in October 2011 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of the topic. The topic has been restructured to improve clarity and navigation. Recommendations on managing people who have had an inadequate response to the standard licensed dose of antihistamine have been changed to include the option to double the standard licensed dose of the first choice antihistamine, before considering referral to secondary care for further management. Issued in January 2012.</p><p><strong>March 2011</strong> — topic structure revised to ensure consistency across CKS topics. No changes to clinical recommendations have been made.</p><p><strong>April 2008</strong> — minor update. Information included from the British Society for Allergy and Clinical Immunology (BSACI) guidelines for the management of chronic urticaria and angio-oedema (2007). Issued in May 2008.</p><p><strong>January 2008</strong> — minor update. Updated in line with guidelines for the evaluation and management of urticaria in adults and children from the British Association of Dermatologists (BAD, 2007). Issued in February 2008.</p><p><strong>January to April 2007</strong> — this is a new CKS topic, replacing the CKS guidance on <em>Urticaria and angio-oedema</em>. The evidence base has been reviewed in detail, and recommendations are more clearly justified and more transparently linked to the supporting evidence. There are no major changes to the recommendations.</p><p><strong>January 2006</strong> — minor update. Black triangle removed from desloratadine. Issued in February 2006.</p><p><strong>October 2005</strong> — minor technical update. Issued in November 2005.</p><p><strong>July 2005</strong> — new CKS patient information leaflet attached. Issued in July 2005.</p><p><strong>January 2004</strong> — written. Validated in March 2004 and issued in June 2004.</p><!-- end field b6503804-2eaf-490d-93cc-1f57cfca5c53 --><!-- end item d8dea68b-59e2-4018-becd-f56788edb72c -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}